KIORA PHARMACEUTICALS INC awarded Lane Keith J. 55,000 derivative securities on 2026-09-17, leaving him with 55,000 derivative securities. For investors, the transaction establishes a new insider position and shows that the disclosed award represents 100.0% of his resulting derivative-securities holding in KIORA Pharmaceuticals.
Key Highlights
- Lane Keith J. received 55,000 derivative securities from KIORA PHARMACEUTICALS INC on 17 September 2026.
- The transaction left Lane Keith J. with 55,000 derivative securities.
- The awarded securities represented about 100.0% of his resulting derivative-securities holding.
55,000 Derivative Securities Awarded
KIORA PHARMACEUTICALS INC (NASDAQ: KPRX) is a Pharmaceuticals: Major company. After the transaction, Lane Keith J.’s reported derivative-securities holding stood at 55,000. The transaction was recorded on 17 September 2026. The related disclosure identifies Lane Keith J. as an insider of KIORA Pharmaceuticals.
New Position Equals 100.0% of Resulting Holding
The reported award accounts for about 100.0% of Lane Keith J.’s resulting derivative-securities holding in KIORA Pharmaceuticals. The disclosure also classifies the event as a new insider position.
FAQs
Q: How many derivative securities did Lane Keith J. receive from KIORA Pharmaceuticals?
A: Lane Keith J. received 55,000 derivative securities from KIORA PHARMACEUTICALS INC on 17 September 2026.
Q: What was Lane Keith J.’s resulting KPRX derivative-securities holding?
A: Lane Keith J.’s resulting derivative-securities holding in KIORA Pharmaceuticals was 55,000. The holding followed the award recorded on 17 September 2026.
Q: What percentage of the resulting holding did the KIORA insider award represent?
A: The transaction represented about 100.0% of Lane Keith J.’s resulting derivative-securities holding in KIORA Pharmaceuticals. It was identified as a new insider position.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.